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Objectives: To clarify the difference between the interim EQ-5D-5L score and 
EQ-5D-5L Japanese scoring, and to evaluate the validity of them. MethOds: Five 
hundred and twenty six patients who received rehabilitation program in six hos-
pitals were asked to administer the EQ-5D-5L. Their occupational therapists were 
simultaneously administered the EQ-5D-5L as proxy respondents to assess their 
health-related quality of life (HRQL). The score of the EQ-5D-5L were calculated by 
the interim value set and new Japanese scoring algorism. The new algorism used TTO 
model was developed by Japanese EQ-5D team as the national tariff. Pearson’s cor-
relations were used to evaluate the concurrent validity of the EQ-5D-5L. Results: 
Mean age of the patients was 67.1 years. Three hundred and twenty one were male 
(60.1%). The mean scores of the interim EQ-5D-5L score and Japanese scoring were 
0.515 (95%CI; 0.493-0.538) and 0.547 (95%CI; 0.526-0.567), respectively. Significantly 
results in two tariffs were observed by the modified Rankin scale (mRS) in: mRS1 
(0.805 vs 0.850), mRS2 (0.682 vs 0.729), mRS3 (0.604 vs 0.618), mRS4 (0.400 vs 0.410), 
mRS5 (0.081 vs 0.201). In particular, the strong difference was observed in 5 level of 
the modified Rankin scale (0.081 vs 0.201). The correlation between the interim score 
and new Japanese scoring was 0.946. cOnclusiOns: The new Japanese tariff for 
EQ-5D-5L indicated high validity, but had a few differences with the interim value. 
We have to mind the differences when use it.
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Objectives: This systematic literature review (SLR) aimed to identify and evaluate 
utilities reported for acute and chronic stroke, myocardial infarction (MI), and angina 
in Europe. MethOds: A SLR was conducted in Embase, PubMed, and the grey litera-
ture between 1992 and January 2015 using keywords for cardiovascular (CV) events 
and utilities. Studies reporting utilities for stroke, angina, acute coronary syndrome 
(ACS) and MI were included. An ongoing review is examining utilities for heart fail-
ure (HF). Results: Sixty-four articles reported on studies in Europe. Study designs 
included trials (17), surveys (21), observational cohorts (22), and post-hoc analyses 
such as meta-analyses (4). Nearly all (53) reported EQ-5D utilities; only three elic-
ited utilities from general populations evaluating hypothetical health states. Across 
the studies, average utilities varied substantially in each of the CV events (stroke: 
-0.14 to 0.961; MI: 0.323 to 0.9; angina: 0.36 to 0.845). Severity of disease, time since 
event, and method of elicitation all appeared to impact utility values. Three studies 
reporting utilities elicited from general populations (stroke: 0.14 to 0.55, MI: 0.45, 
angina: NR) tended to report lower utilities than those obtained from CV patients. 
The ranges of utility values from the general population were similar to those in the 
most recent published vignette study (Matza, 2015) which distinguished between 
chronic post-event health states and acute health states and includes the event and 
its immediate impact (stroke: 0.33 to 0.52, ACS: 0.67 to 0.82). cOnclusiOns: This 
SLR identified a wide range of utility values for stroke, MI, and angina in Europe. 
Method of elicitation, severity of disease, and time since event may impact utility 
values. Future studies of CV event utilities should evaluate the differences in utility 
values by type of respondent and method of elicitation.
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Objectives: To describe how health-related quality of life(HRQL) is being affected 
by disease in heart failure(HF) patients; moreover, to measure health utility values 
in HF patients and analyze their relationships with different clinical and patient 
variables. MethOds: 1398 HF diagnosed patients in Basque Country hospitals were 
consecutively recruited and followed-up for 12 months, upon discharged from hos-
pital due to admission for HF. Besides clinical variables, patient reported outcomes, 
EQ5D-3L, SF-12 and Minnesota Living with Heart Failure(MLHF) questionnaires, were 
recorded on inclusion, 6 and 12 months. Utilities were calculated with Spanish 
EQ5D3L TTO tariff. For bivariate analyses, parametric or non-parametric differences 
in means, proportions and correlations were used, as appropriate. We explored 
determinants of baseline utility and drivers of change over 1 year with OLS regres-
sion with robust standard errors. Results: Mean age was 78.0 years(SD:10.2), 88.9% 
older than 65; 53.7% men, 54.1% had left ventricular ejection fraction of 50% or more, 
28.8 months mean disease duration, median= 2 of Charlson Index, and 28.3% of HFs 
had an ischemic origin. Mostly, patient were rated as NYHA II(56.4%) or III(40.4%). 
Only 78.8% patients were alive after 12 months. EQ5D Mobility and Usual Activities 
dimensions were the most affected (81.7% and 82.1% patients reporting problems). 
Usual EQ5D ceiling effect was not seen in HF patients: 6.3% patients reported no 
problems at all. Mean(SD) basal utility index was 0.430(0.401), but increased after 
12 months follow-up[0.565(0.398)] probably due to survival bias. Mean utility values 
were significantly lower at baseline for those who died before the end of study 
(diff.= -0.155; p< 0.001). Baseline mean utility index correlated negatively with MLHF 
total score (r= -0.388;p< 0.001). Sex, age, and baseline Charlson, MLHF and ejection 
fraction were predictive of HRQL at 12 months, but not NYHA. cOnclusiOns: HF 
affects deeply to patients’ HRQL; the scope of predictive variables differ over time.
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Objectives: Cancer patients are at high risk of venous thromboembolism (VTE), 
provoked by the cancer, chemotherapies or co-morbidities. The CATCH trial inves-
to follow-up time without any bleed. Similar results were observed for GP consulta-
tions and hospitalizations (despite absence of a linear pattern). cOnclusiOns: In 
NVAF patients treated with VKA, the first and subsequent bleeds led to an increased 
risk of healthcare resource utilisation. Healthcare payers, as well as patients and clini-
cians, would therefore benefit from clinical strategies to help prevent the first bleed.
CARdiOVASCulAR diSORdeRS – Patient-Reported Outcomes & Patient  
Preference Studies
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Objectives: To determine in an urban community health population with hyperten-
sion (HTN), whether patient beliefs concerning HTN medication use as revealed by 
responses to Beliefs about Medicines Questionnaire (BMQ, Horne 1999) were affected 
by nine variables: age, gender, education, family or friend with HTN or stroke, adher-
ence, living with someone. MethOds: After approval from Northeastern University’s 
Institutional Review Board, a convenience sample of patients was asked to com-
plete the BMQ prior to routine HTN follow-up appointments at a Boston community 
health center between 5/2014-9/2014. Researchers screened for eligibility (English 
speaking, taking anti-hypertensive medication), described the study, and requested 
informed consent. Patients completed background demographic questions and a 
hypertension medication modified BMQ (BMQ: 18 items; 5 levels: 5= strongly agree, 
1= strongly disagree; 4 factors). Results: 99 patients averaged 58.3yo±11.7SD, 52.3% 
female. Overall BMQ factor scores were: Specific Necessity (SN), 2.67±0.75; Specific 
Concerns (SC), 3.28±0.79; General Overuse (GO), 3.14± ±0.86 and General Harm (GH), 
3.69±0.69. Initial bivariate analyses indicate no differences in impact of demographic 
variables on SN. However three factors were influenced by demographic variables: SC 
affected by gender (males 3.48±0.81, females 3.09±0.73, p= 0.014) and living with some-
one (“Yes” 3.14±0.78, “No” 3.59±0.77, p= 0.01); GO affected by gender (males 3.36±0.9, 
females 2.96±0.79, p= 0.019), living with someone (“Yes” 3.03±0.86, “No” 3.40±0.83, 
p= 0.05), and race (“white” 3.31±0.78, “black” 2.77±0.97, “latino” 3.40±0.80, “Asian” 
2.5±0.70, p= 0.02); and GH affected by adherence (“Yes” 3.77±0.68, “No” 3.36±0.63, 
p= 0.02) and race (“white” 3.83±0.54, “black” 3.50±0.84, “latino” 3.50±0.64, “Asian” 
2.81±0.95, p= 0.007). CONCLUSIONS: This study provides BMQ factor scores for urban 
HTN patients. Additionally insight is provided into the effect of patient demographics 
and life characteristics on BMQ factor scores. Individual patient BMQ scores have the 
potential to assist health providers in tailoring patient-specific medication counseling 
programs to increase perception of need for anti-hypertensive medication necessity 
and reduce patient-specific medication harm concerns.
PCV132
QuAlity Of life And emOtiOnAl imPACt Of A fixed dOSe COmbinAtiOn 
Of AntiHyPeRtenSiVe dRugS in PAtientS witH unCOntROlled 
HyPeRtenSiOn
Schmieder RE1, Fronk E2, Alexandre AF2, Bramlage P3
1Universitätsklinikum Erlangen, Erlangen, Germany, 2Daiichi Sankyo Europe, Munich, Germany, 
3IPPMed, Cloppenburg, Germany
Objectives: Uncontrolled hypertension can be associated with not only physical 
symptoms, but also with a significant emotional burden. However, so far only few 
studies described the emotional burden. Furthermore, the effects of antihyperten-
sive therapies on the physical and mental aspects of quality of life for hypertensive 
patients remain unclear. Here, we analyse changes in health-related quality of life 
in patients receiving a fixed dose combination (FDC) of the three antihyperten-
sive drugs olmesartan, amlodipine and hydrochlorothiazide. MethOds: A series 
of questions about patients’ perceptions regarding the impact of uncontrolled 
hypertension on their lives were incorporated into the SeviTarget study. It was 
carried out between 11/2012 and 12/2013. Patients completed three questionnaires 
on their overall health, their attitudes and level of apprehension about manag-
ing blood pressure (Schmieder J Hypertens 2013) and SF-12 at baseline and at a 
follow-up visit 24-week later or at the last available visit. Results: A total of 5,831 
patients (63.5±11.8 years, 47.0% female) were recruited in Austria and Germany. 
High proportion of patients had cardiovascular risk factors, with diabetes melli-
tus (29.4%) and metabolic syndrome (21.1%) being the most prevalent. Following 
approximately 24-week of treatment, the mean reduction in systolic/diastolic 
BP was 29.0/14.0mmHg. Patients´ responses to the questionnaires demonstrated 
improvements in many factors related to quality of life. At baseline only 33.3% 
of patients described their current state of health as good or excellent, while at 
follow-up this value had risen to 75.8%. Responses regarding physical factors such as 
symptoms and limitations in activities, and mental factors such anxiety associated 
with treatment, all improved during antihypertensive drug treatment. Changes to 
more optimistic responses were more likely for patients that achieved a target BP of 
< 140/90mmHg. cOnclusiOns: The study demonstrates the great improvements 
in quality of life that can be achieved with effective management of hypertension.
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